

## Urea Cycle Disorders Consortium

### Abstracts Presented at Conferences

1. Lichter-Konecki U, Cabrera-Luque J, Moses L, Gallo V. Identifying astrocyte functions altered during hyperammonemic encephalopathy. Paper presented at: Society for Neuroscience Annual Meeting; November 12-16, 2005; Washington, DC.
2. Tuchman M. Collaborative Investigations of Urea Cycle Disorders: The Importance of Research Networks in the Study of Rare Diseases. Paper presented at: American Society of Human Genetics Annual Meeting; October 23-27, 2007; San Diego, CA.
3. Gropman A. 13C MRS study of ornithine transcarbamylase deficiency (OTCD). Paper presented at: Society for Inherited Metabolic Disorders Meeting; March, 2008; Asilomar, CA.
4. Kahn I, Seltzer R, Van Meter J, Gropman A. Diffusion tensor imaging detects areas of abnormal white matter microstructure in patients with partial ornithine transcarbamylase deficiency (OTCD). Paper presented at: Society for Inherited Metabolic Disorders Meeting; March, 2008; Asilomar, CA.
5. Tuchman M. Setting up Multi-Institutional Network Research in Rare Diseases: The Urea Cycle Consortium. Paper presented at: Society for Inherited Metabolic Disorders Meeting; March, 2008; Asilomar, CA
6. Lee B. Urea cycle disorders best practices and new developments: clinical presentation, laboratory diagnosis, and chronic management. Paper presented at: American College of Medical Genetics Annual Clinical Genetics Meeting; March 12-16, 2008; Phoenix, AZ.
7. Lichter-Konecki U. A Rare Disease Clinical Research Consortium for the collaborative investigation of UCDs Paper presented at: Pediatric Academic Societies Annual Meeting; May, 2009; Baltimore, MD.
8. Batshaw M. The Urea Cycle Disorders Consortium. Paper presented at: National Urea Cycle Disorders Foundation; July, 2009; Pasadena, California.
9. Batshaw M. The Urea Cycle Disorders Consortium. Paper presented at: Satellite Symposium to the 11<sup>th</sup> International Congress on Inborn Errors of Metabolism; August, 2009; La Jolla, California.
10. Batshaw M. Setting up multi-institutional research network in rare disease: The Urea Cycle Disorders Consortium. Paper presented at: Institute of Medicine Committee on Accelerating Rare Diseases Research and Orphan Product Development; November 23, 2009.
11. Gropman A, Shattuck K, Prust M, et al. Increased dorsolateral prefrontal cortex activation in OTCD during working memory. Paper presented at: National Urea Cycle Disorders Foundation Annual Conference; July 9-11, 2010; Cambridge, MA.
12. Krivitzky L, Waisbren S. Neuropsychological Functioning in Rare Diseases; Research Challenges and Potential Solutions. Paper presented at: 39th Annual Meeting of the International Neuropsychological Society; February 2-5, 2011; Boston, MA.

- 13.** Breedan A, Prust M, Krivitzky L, Gropman A. Cognitive Tests Sensitive to the Neurological Impairment in Ornithine Transcarbamylase Deficiency (OTCD). Paper presented at: 34th Annual Meeting of the Society for Inherited Metabolic Disorders; February 27 - March 2, 2011; Asilomar, CA.
- 14.** Lichter U. Update on the urea cycle disorders registry. Paper presented at: 34th Annual Meeting of the Society for Inherited Metabolic Disorders; February 27 - March 2, 2011; Asilomar, CA.
- 15.** Shattuck K, Prust M, Seltzer R, et al. Increased Dorsolateral Prefrontal Cortex Activation in Ornithine Transcarbamylase Deficiency (OTCD) During Working memory: An fMRI study. Paper presented at: Society for Inherited Metabolic Disorders Annual Conference; February 27 - March 2, 2011; Asilomar, CA.
- 16.** Shattuck K, Prust M, Seltzer R, Hailu A, vanMeter J, Gropman A. Altered Neural Activation in ornithine Transcarbamylase Deficiency during working memory. Paper presented at: Society for Inherited Metabolic Disorders Annual Conference; February 27 - March 2, 2011; Asilomar, CA.
- 17.** Batshaw M. The Urea Cycle Disorders Consortium (UCDC). Paper presented at: 4th Annual Rare Disease Day February 28, 2011; Bethesda, MD.
- 18.** Gropman A, Shattuck K, Prust M, et al. Increased dorsolateral prefrontal cortex activation in OTCD during working memory. Paper presented at: 11th International Congress of the European Society for Magnetic Resonance in Neuropediatrics; March 24-26, 2011; Amsterdam, The Netherlands.
- 19.** Batshaw M. Data Quality Challenges of Multisite Clinical Trials Panel. Paper presented at: Quality Data from Pediatric Clinical Trials Meeting; October 21, 2011; Bethesda, MD.
- 20.** Diaz G, Krivitzky L, Mokhtarani M, et al. Ammonia (NH<sub>3</sub>) Control and Improved Neurocognitive Outcome Among Urea Cycle Disorder (UCD) Patients Treated with Glycerol Phenylbutyrate (GPB). Paper presented at: American College of Medical Genetics Conference; March 27-31, 2012; Charlotte, NC.
- 21.** Diaz G, Krivitzky L, Mokhtarani M, et al. Ammonia (NH<sub>3</sub>) Control and Improved Neurocognitive Outcome Among Urea Cycle Disorder (UCD) Patients Treated with Glycerol Phenylbutyrate (GPB). Paper presented at: Society for Inherited Metabolic Disorders Annual Conference March 31 - April 2, 2012; Charlotte, NC.
- 22.** Ludwig W, Ellenbogen A, Gropman A. MD-Fiber Tracts in the Corpus Callosum Correlate with Scores on Behavioral Tasks and Glutamine Levels in Patients with OTCD, initial study (selected for travel award). Paper presented at: Society for Inherited Metabolic Disorders Annual Conference; March 31 - April 2, 2012; Charlotte, NC.
- 23.** Mokhtarani M, Diaz G, Rhead W, et al. Elevated Phenylacetic Acid (PAA) Levels Appear Linked to Neurological Adverse Events in Healthy Adults But Not in Urea Cycle Disorder (UCD) Patients.

Paper presented at: Society for Inherited Metabolic Disorders Annual Conference; March 31 - April 2, 2012; Charlotte, NC.

24. Monteleone J, Mokhtarani M, Diaz G, et al. Population PK Analysis of Glycerol Phenylbutyrate (GPB) and Sodium Phenylbutyrate (NaPBA) in Adult and Pediatric Patients with Urea Cycle Disorders (UCD). Paper presented at: Society for Inherited Metabolic Disorders Annual Conference; March 31 - April 2, 2012; Charlotte, NC.
25. Mokhtarani M, Diaz G, Rhead W, et al. Urinary Phenylacetateylglutamine Appears to Be a More Useful Marker than Metabolite Blood Levels for Therapeutic Monitoring of Phenylacetic Acid (PAA) Prodrugs. Paper presented at: Society for Inherited Metabolic Disorders Annual Conference; March 31 - April 2, 2012; Charlotte, NC.
26. Diaz G, Mokhtarani M, Rhead W, et al. Ammonia (NH<sub>3</sub>) amino acid and hyperammonemic crises (HACS) in pediatric and adult patients with urea cycle disorders (UCDS) during dosing with sodium phenylbutyrate (NaPBA) vs. Glycerol phenylbutyrate (GPB). Paper presented at: Garrod Association Symposium; May 31 - June 1, 2013; Sherbrooke, Canada.
27. Lee B, Mokhtarani M, Diaz G, et al. Optimizing ammonia (NH<sub>3</sub>) control in urea cycle disorder (UCD) patients: short and long-term implications. Paper presented at: Garrod Association Symposium; May 31 - June 1, 2013; Sherbrooke, Canada.
28. Diaz G, Mokhtarani M, Rhead W, et al. Ammonia (NH<sub>3</sub>) amino acid and hyperammonemic crises (HACS) in pediatric and adult patients with urea cycle disorders (UCDS) during dosing with sodium phenylbutyrate (NaPBA) vs. Glycerol phenylbutyrate (GPB). Paper presented at: 31st Annual Meeting of the Southeastern Regional Genetics Group™, Inc July 18-20, 2013; Asheville, NC.
29. Lee B, Mokhtarani M, Diaz G, et al. Optimizing ammonia (NH<sub>3</sub>) control in urea cycle disorder (UCD) patients: short and long-term implications. Paper presented at: 12th International Congress of Inborn Errors of Metabolism; September 3-6, 2013; Barcelona, Spain.

## Conference Proceedings

1. Patrick TB, Richesson R, Andrews JE, Folk LC. SNOMED CT coding variation and grouping for "other findings" in a longitudinal study on urea cycle disorders. *AMIA. Annu. Symp. Proc.* 2008:11-15.
2. Bhavsar S, Khalidi N, Carette S, et al. Venothromboembolism in Large Vessel Vasculitis. Paper presented at: American College of Rheumatology (ACR/ARHP) Annual Meeting; October 2014, 2014; Boston, MA.
3. Carmona F, Mackie S, Martin J, et al. An Immunochip Study Confirms a Strong Contribution of HLA Class I and II Genes in the Susceptibility to Giant Cell Arteritis. Paper presented at: American College of Rheumatology (ACR/ARHP) Annual Meeting 2014; Boston, MA.
4. Mecoli C, Wang F, Pappas C, et al. The Relationship of ARMS2 Genotype with Idiopathic Inflammatory Vasculitis. Paper presented at: American College of Rheumatology (ACR/ARHP) Annual Meeting 2014; Boston, MA.

5. A R-P, Warner R, Cuthbertson D, et al. Biomarkers of Disease Activity in Vasculitis. Paper presented at: American College of Rheumatology (ACR/ARHP) Annual Meeting 2014; Boston, MA.
6. Sreih A, Ezzeddine R, Fan J, et al. The Role of Macrophage Migration Inhibitory Factor (MIF) and MIF Gene Polymorphisms in the Pathogenesis of Granulomatosis with Polyangiitis. Paper presented at: American College of Rheumatology (ACR/ARHP) Annual Meeting 2014; Boston, MA.
7. Sy A, Dehghan N, Khalidi N, et al. Vasculitis and Inflammatory Bowel Diseases: A Study of 32 Patients with Both Conditions and Systematic Review of the Literature. Paper presented at: American College of Rheumatology (ACR/ARHP) Annual Meeting 2014; Boston, MA.

## Journal Articles

1. Kleppe S, Mian A, Lee B. Urea Cycle Disorders. *Curr. Treat. Options Neurol.* Jul 2003;5(4):309-319. PMID: 12791198
2. Gropman AL, Batshaw ML. Cognitive outcome in urea cycle disorders. *Mol. Genet. Metab.* Apr 2004;81 Suppl 1:S58-62. PMID: 15050975
3. Mian A, McCormack WM, Jr., Mane V, Kleppe S, Ng P, Finegold M, O'Brien WE, Rodgers JR, Beaudet AL, Lee B. Long-term correction of ornithine transcarbamylase deficiency by WPRE-mediated overexpression using a helper-dependent adenovirus. *Mol. Ther.* Sep 2004;10(3):492-499. PMID: 15336649
4. Caldovic L, Morizono H, Daikhin Y, et al. Restoration of ureagenesis in N-acetylglutamate synthase deficiency by N-carbamylglutamate. *J. Pediatr.* Oct 2004;145(4):552-554. PMID: 15480384
5. Scaglia F, Brunetti-Pierri N, Kleppe S, Marini J, Carter S, Garlick P, Jahoor F, O'Brien W, Lee B. Clinical consequences of urea cycle enzyme deficiencies and potential links to arginine and nitric oxide metabolism. *J. Nutr.* Oct 2004;134(10 Suppl):2775S-2782S; discussion 2796S-2797S. PMID: 15465784
6. Crombez EA, Cederbaum SD. Hyperargininemia due to liver arginase deficiency. *Mol. Genet. Metab.* Mar 2005;84(3):243-251. PMID: 15694174
7. Gropman AL. Expanding the diagnostic and research toolbox for inborn errors of metabolism: the role of magnetic resonance spectroscopy. *Mol. Genet. Metab.* Sep-Oct 2005;86(1-2):2-9.
8. Summar ML, Barr F, Dawling S, et al. Unmasked adult-onset urea cycle disorders in the critical care setting. *Crit. Care Clin.* Oct 2005;21(4 Suppl):S1-8. PMID: 16227111
9. Lanpher B, Brunetti-Pierri N, Lee B. Inborn errors of metabolism: the flux from Mendelian to complex diseases. *Nat. Rev. Genet.* Jun 2006;7(6):449-460. PMID: 16708072
10. Eeds AM, Mortlock D, Wade-Martins R, Summar ML. Assessing the functional characteristics of synonymous and nonsynonymous mutation candidates by use of large DNA constructs. *Am. J. Hum. Genet.* Apr 2007;80(4):740-750. PMID: 17357079, PMCID: PMC1852709
11. Gropman AL, Summar M, Leonard JV. Neurological implications of urea cycle disorders. *J. Inher. Metab. Dis.* Nov 2007;30(6):865-879. PMID: 18038189, PMCID: PMC3758693
12. Gropman AL, Seltzer RR, Yudkoff M, Sawyer A, VanMeter J, Fricke ST. 1H MRS allows brain phenotype differentiation in sisters with late onset ornithine transcarbamylase deficiency

(OTCD) and discordant clinical presentations. *Mol. Genet. Metab.* May 2008;94(1):52-60. PMID: 18262815, PMCID: PMC2486377

13. Tuchman M, Caldovic L, Daikhin Y, et al. N-carbamylglutamate markedly enhances ureagenesis in N-acetylglutamate deficiency and propionic acidemia as measured by isotopic incorporation and blood biomarkers. *Pediatr. Res.* Aug 2008;64(2):213-217. PMID: 18414145, PMCID: PMC2640836
14. Tuchman M, Lee B, Lichter-Konecki U, Summar ML, Yudkoff M, Cederbaum SD, Kerr DS, Diaz GA, Seashore MR, Lee HS, McCarter RJ, Krischer JP, Batshaw ML. Cross-sectional multicenter study of patients with urea cycle disorders in the United States. *Mol. Genet. Metab.* Aug 2008;94(4):397-402. PMID: 18562231, PMCID: PMC2640937
15. Brunetti-Pierri N, Clarke C, Mane V, Palmer DJ, Lanpher B, Sun Q, O'Brien W, Lee B. Phenotypic correction of ornithine transcarbamylase deficiency using low dose helper-dependent adenoviral vectors. *J. Gene Med.* Aug 2008;10(8):890-896. PMID: 18563850, PMCID: PMC2766563
16. Deardorff MA, Gaddipati H, Kaplan P, Sanchez-Lara PA, Sondheimer N, Spinner NB, Hakonarson H, Ficicioglu C, Ganesh J, Markello T, Loechelt B, Zand DJ, Yudkoff M, Lichter-Konecki U. Complex management of a patient with a contiguous Xp11.4 gene deletion involving ornithine transcarbamylase: a role for detailed molecular analysis in complex presentations of classical diseases. *Mol. Genet. Metab.* Aug 2008;94(4):498-502. PMID: 18524659, PMCID: PMC2572572
17. Gropman AL, Fricke ST, Seltzer RR, Hailu A, Adeyemo A, Sawyer A, van Meter J, Gaillard WD, McCarter R, Tuchman M, Batshaw M. 1H MRS identifies symptomatic and asymptomatic subjects with partial ornithine transcarbamylase deficiency. *Mol. Genet. Metab.* Sep-Oct 2008;95(1-2):21-30. PMID: 18662894, PMCID: PMC3724938
18. Sailasuta N, Robertson LW, Harris KC, Gropman AL, Allen PS, Ross BD. Clinical NOE 13C MRS for neuropsychiatric disorders of the frontal lobe. *J. Magn. Reson.* Dec 2008;195(2):219-225. PMID: 18829354, PMCID: PMC2610418
19. Gropman A, Rigas A. Neurometabolic disorders: urea-cycle disorder, outcomes, development and treatment. *Pediatric Health.* December 2008;2(6):701-713.
20. Richesson RL, Lee HS, Cuthbertson D, Lloyd J, Young K, Krischer JP. An automated communication system in a contact registry for persons with rare diseases: scalable tools for identifying and recruiting clinical research participants. *Contemp. Clin. Trials.* Jan 2009;30(1):55-62. PMID: 18804556, PMCID: PMC2640948
21. Krivitzky L, Babikian T, Lee HS, Thomas NH, Burk-Paull KL, Batshaw ML. Intellectual, adaptive, and behavioral functioning in children with urea cycle disorders. *Pediatr. Res.* Jul 2009;66(1):96-101. PMID: 19287347, PMCID: PMC2746951
22. Venkateswaran L, Scaglia F, McLin V, Hertel P, Shchelochkov OA, Karpen S, Mahoney D, Jr., Yee DL. Ornithine transcarbamylase deficiency: a possible risk factor for thrombosis. *Pediatr. Blood Cancer.* Jul 2009;53(1):100-102. PMID: 19343772
23. Gropman AL, Sailasuta N, Harris KC, Abulseoud O, Ross BD. Ornithine transcarbamylase deficiency with persistent abnormality in cerebral glutamate metabolism in adults. *Radiology.* Sep 2009;252(3):833-841. PMID: 19567648, PMCID: PMC2734894

24. Brunetti-Pierri N, Erez A, Shchelochkov O, Craigen W, Lee B. Systemic hypertension in two patients with ASL deficiency: a result of nitric oxide deficiency? *Mol. Genet. Metab.* Sep-Oct 2009;98(1-2):195-197. PMID: 19592285, PMCID: PMC2746757
25. Mc Guire PJ, Parikh A, Diaz GA. Profiling of oxidative stress in patients with inborn errors of metabolism. *Mol. Genet. Metab.* Sep-Oct 2009;98(1-2):173-180. PMID: 19604711, PMCID: PMC2915835
26. Ah Mew N, Payan I, Daikhin Y, Nissim I, Tuchman M, Yudkoff M. Effects of a single dose of N-carbamylglutamate on the rate of ureagenesis. *Mol. Genet. Metab.* Dec 2009;98(4):325-330. PMID: 19660971, PMCID: PMC2784258
27. Seminara J, Tuchman M, Krivitzky L, Krischer J, Lee HS, Lemons C, Baumgartner M, Cederbaum S, Diaz GA, Feigenbaum A, Gallagher RC, Harding CO, Kerr DS, Lanpher B, Lee B, Lichter-Konecki U, McCandless SE, Merritt JL, Oster-Granite ML, Seashore MR, Stricker T, Summar M, Waisbren S, Yudkoff M, Batshaw ML. Establishing a consortium for the study of rare diseases: The Urea Cycle Disorders Consortium. *Mol. Genet. Metab.* 2010;100 Suppl 1:S97-105. PMID: 20188616, PMCID: PMC2858794
28. Yudkoff M, Ah Mew N, Daikhin Y, Horyn O, Nissim I, Payan I, Tuchman M. Measuring in vivo ureagenesis with stable isotopes. *Mol. Genet. Metab.* 2010;100 Suppl 1:S37-41. PMID: 20338795, PMCID: P MC2858793
29. Caldovic L, Ah Mew N, Shi D, Morizono H, Yudkoff M, Tuchman M. N-acetylglutamate synthase: structure, function and defects. *Mol. Genet. Metab.* 2010;100 Suppl 1:S13-19. PMID: 0303810, PMCID: PMC2876818
30. Campeau PM, Pivalizza PJ, Miller G, McBride K, Karpen S, Goss J, Lee BH. Early orthotopic liver transplantation in urea cycle defects: follow up of a developmental outcome study. *Mol. Genet. Metab.* 2010;100 Suppl 1:S84-87. PMID: 20223690, PMCID: PMC2867349
31. Deignan JL, De Deyn PP, Cederbaum SD, Fuchshuber A, Roth B, Gsell W, Marescau B. Guanidino compound levels in blood, cerebrospinal fluid, and post-mortem brain material of patients with argininemia. *Mol. Genet. Metab.* 2010;100 Suppl 1:S31-36. PMID: 20176499
32. Gropman A. Brain imaging in urea cycle disorders. *Mol. Genet. Metab.* 2010;100 Suppl 1:S20-30. PMID: 20207564, PMCID: PMC3258295
33. Oldham MS, VanMeter JW, Shattuck KF, Cederbaum SD, Gropman AL. Diffusion tensor imaging in arginase deficiency reveals damage to corticospinal tracts. *Pediatr. Neurol.* Jan 2010;42(1):49-52. PMID: 20004862, PMCID: PMC3758690
34. Ah Mew N, McCarter R, Daikhin Y, Nissim I, Yudkoff M, Tuchman M. N-carbamylglutamate augments ureagenesis and reduces ammonia and glutamine in propionic acidemia. *Pediatrics.* Jul 2010;126(1):e208-214. PMID: 20566609, PMCID: PMC3297024
35. Lee B, Rhead W, Diaz GA, Scharschmidt BF, Mian A, Shchelochkov O, Marier JF, Beliveau M, Mauney J, Dickinson K, Martinez A, Gargosky S, Mokhtarani M, Berry SA. Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control. *Mol. Genet. Metab.* Jul 2010;100(3):221-228. PMID: 20382058, PMCID: PMC2905228
36. Gropman AL, Gertz B, Shattuck K, Kahn IL, Seltzer R, Krivitsky L, Van Meter J. Diffusion tensor imaging detects areas of abnormal white matter microstructure in patients with partial ornithine

transcarbamylase deficiency. *AJNR Am. J. Neuroradiol.* Oct 2010;31(9):1719-1723. PMID: 19287347, PMCID: PMC2746951

37. Shchelochkov OA, Li FY, Wang J, Zhan H, Towbin JA, Jefferies JL, Wong LJ, Scaglia F. Milder clinical course of Type IV 3-methylglutaconic aciduria due to a novel mutation in TMEM70. *Mol. Genet. Metab.* Oct-Nov 2010;101(2-3):282-285. PMID: 20728387
38. Wang J, Shchelochkov OA, Zhan H, Li F, Chen LC, Brundage EK, Pursley AN, Schmitt ES, Haberle J, Wong LJ. Molecular characterization of CPS1 deletions by array CGH. *Mol. Genet. Metab.* Jan 2011;102(1):103-106. PMID: 20855223
39. Erez A, Nagamani SC, Lee B. Argininosuccinate lyase deficiency-argininosuccinic aciduria and beyond. *Am. J. Med. Genet. C Semin. Med. Genet.* Feb 15 2011;157(1):45-53. PMID: 21312326, PMCID: PMC3073162
40. Erez A, Shchelochkov OA, Plon SE, Scaglia F, Lee B. Insights into the pathogenesis and treatment of cancer from inborn errors of metabolism. *Am. J. Hum. Genet.* Apr 8 2011;88(4):402-421. PMID: 21473982, PMCID: PMC3071916
41. Morgan TM, Schlegel C, Edwards KM, Welch-Burke T, Zhu Y, Sparks R, Summar M. Vaccines are not associated with metabolic events in children with urea cycle disorders. *Pediatrics.* May 2011;127(5):e1147-1153. PMID: 21482610, PMCID: PMC3387867
42. Marini JC, Lanpher BC, Scaglia F, O'Brien WE, Sun Q, Garlick PJ, Jahoor F, Lee B. Phenylbutyrate improves nitrogen disposal via an alternative pathway without eliciting an increase in protein breakdown and catabolism in control and ornithine transcarbamylase-deficient patients. *Am. J. Clin. Nutr.* Jun 2011;93(6):1248-1254. PMID: 21490144, PMCID: PMC3095500
43. Haberle J, Shchelochkov OA, Wang J, Katsonis P, Hall L, Reiss S, Eeds A, Willis A, Yadav M, Summar S, Lichtarge O, Rubio V, Wong LJ, Summar M. Molecular defects in human carbamoyl phosphate synthetase I: mutational spectrum, diagnostic and protein structure considerations. *Hum. Mutat.* Jun 2011;32(6):579-589. PMID: 21120950
44. Lichter-Konecki U, Diaz GA, Merritt JL, 2nd, Feigenbaum A, Jomphe C, Marier JF, Beliveau M, Mauney J, Dickinson K, Martinez A, Mokhtarani M, Scharschmidt B, Rhead W. Ammonia control in children with urea cycle disorders (UCDs); phase 2 comparison of sodium phenylbutyrate and glycerol phenylbutyrate. *Mol. Genet. Metab.* Aug 2011;103(4):323-329. PMID: 21612962
45. Jain-Ghai S, Nagamani SC, Blaser S, Siriwardena K, Feigenbaum A. Arginase I deficiency: severe infantile presentation with hyperammonemia: more common than reported? *Mol. Genet. Metab.* Sep-Oct 2011;104(1-2):107-111. PMID: 21802329, PMCID: PMC3171515
46. Heibel SK, Ah Mew N, Caldovic L, Daikhin Y, Yudkoff M, Tuchman M. N-carbamylglutamate enhancement of ureagenesis leads to discovery of a novel deleterious mutation in a newly defined enhancer of the NAGS gene and to effective therapy. *Hum. Mutat.* Oct 2011;32(10):1153-1160. PMID: 21681857
47. Prust MJ, Gropman AL, Hauser N. New frontiers in neuroimaging applications to inborn errors of metabolism. *Mol. Genet. Metab.* Nov 2011;104(3):195-205. PMID: 21778100, PMCID: PMC3758691
48. Wilson JM, Shchelochkov OA, Gallagher RC, Batshaw ML. Hepatocellular carcinoma in a research subject with ornithine transcarbamylase deficiency. *Mol. Genet. Metab.* Feb 2012;105(2):263-265. PMID: 2129577, PMCID: PMC3273986

49. Mitchell S, Welch-Burke T, Dumitrescu L, Lomenick JP, Murdock DG, Crawford DC, Summar M. Peptide tyrosine tyrosine levels are increased in patients with urea cycle disorders. *Mol. Genet. Metab.* May 2012;106(1):39-42. PMID: 22459207, PMCID: PMC3336020
50. Nagamani SC, Erez A, Lee B. Argininosuccinate lyase deficiency. *Genet. Med.* May 2012;14(5):501-507. PMID: 22241104, PMCID: PMC3709024
51. Nagamani SC, Campeau PM, Shchelochkov OA, et al. Nitric-oxide supplementation for treatment of long-term complications in argininosuccinic aciduria. *Am. J. Hum. Genet.* May 2012;90(5):836-846. PMID: 22541557, PMCID: PMC3376491
52. Fike CD, Sidoryk-Wegrzynowicz M, Aschner M, Summar M, Prince LS, Cunningham G, Kaplowitz M, Zhang Y, Aschner JL. Prolonged hypoxia augments L-citrulline transport by system A in the newborn piglet pulmonary circulation. *Cardiovasc. Res.* Aug 1 2012;95(3):375-384. PMID: 22673370, PMCID: PMC3400357
53. Nagamani SC, Lee B, Erez A. Optimizing therapy for argininosuccinic aciduria. *Mol. Genet. Metab.* Sep 2012;107(1-2):10-14. PMID: 22841516, PMCID: PMC3444682
54. Nagamani SC, Shchelochkov OA, Mullins MA, Carter S, Lanpher BC, Sun Q, Kleppe S, Erez A, O'Brian Smith E, Marini JC, Lee B. A randomized controlled trial to evaluate the effects of high-dose versus low-dose of arginine therapy on hepatic function tests in argininosuccinic aciduria. *Mol. Genet. Metab.* Nov 2012;107(3):315-321. PMID: 23040521, PMCID: PMC3483446
55. Gropman AL. Patterns of brain injury in inborn errors of metabolism. *Semin. Pediatr. Neurol.* Dec 2012;19(4):203-210. PMID: 23245553, PMCID: PMC3758694
56. Ah Mew N, Krivitzky L, McCarter R, Batshaw M, Tuchman M. Clinical outcomes of neonatal onset proximal versus distal urea cycle disorders do not differ. *J. Pediatr.* Feb 2013;162(2):324-329 e321. PMID: 22901741, PMCID: PMC4440324
57. Ferriero R, Manco G, Lamantea E, et al. Phenylbutyrate therapy for pyruvate dehydrogenase complex deficiency and lactic acidosis. *Sci Transl Med.* Mar 6 2013;5(175):175ra131. PMID: 23467562
58. Gropman AL, Shattuck K, Prust MJ, et al. Altered neural activation in ornithine transcarbamylase deficiency during executive cognition: an fMRI study. *Hum. Brain Mapp.* Apr 2013;34(4):753-761. PMID: 22110002, PMCID: PMC3338900
59. Smith W, Diaz GA, Lichter-Konecki U, et al. Ammonia control in children ages 2 months through 5 years with urea cycle disorders: comparison of sodium phenylbutyrate and glycerol phenylbutyrate. *J. Pediatr.* Jun 2013;162(6):1228-1234, 1234 e1221. PMID: 23324524
60. Diaz GA, Krivitzky LS, Mokhtarani M, et al. Ammonia control and neurocognitive outcome among urea cycle disorder patients treated with glycerol phenylbutyrate. *Hepatology.* Jun 2013;57(6):2171-2179. PMID: 22961727, PMCID: PMC3557606
61. Gropman AL, Prust M, Breeden A, Fricke S, VanMeter J. Urea cycle defects and hyperammonemia: effects on functional imaging. *Metab. Brain Dis.* Jun 2013;28(2):269-275. PMID: 23149878, PMCID: PMC3594356
62. Lichter-Konecki U, Nadkarni V, Moudgil A, et al. Feasibility of adjunct therapeutic hypothermia treatment for hyperammonemia and encephalopathy due to urea cycle disorders and organic acidemias. *Mol. Genet. Metab.* Aug 2013;109(4):354-359. PMID: 23791307



63. Zhong L, Li S, Li M, et al. Vector sequences are not detected in tumor tissue from research subjects with ornithine transcarbamylase deficiency who previously received adenovirus gene transfer. *Hum. Gene Ther.* Sep 2013;24(9):814-819. PMID: 24010702, PMCID: PMC3768231
64. Summar ML, Koelker S, Freedenberg D, et al. The incidence of urea cycle disorders. *Mol. Genet. Metab.* Sep-Oct 2013;110(1-2):179-180. PMID: 23972786
65. McGuire PJ, Lee HS, Summar ML. Infectious precipitants of acute hyperammonemia are associated with indicators of increased morbidity in patients with urea cycle disorders. *J. Pediatr.* Dec 2013;163(6):1705-1710 e1701. PMID: 24084106, PMCID: PMC3958925
66. Landau YE, Lichter-Konecki U, Levy HL. Genomics in newborn screening. *J. Pediatr.* Jan 2014;164(1):14-19. PMID: 23992678
67. Gallagher RC, Lam C, Wong D, Cederbaum S, Sokol RJ. Significant hepatic involvement in patients with ornithine transcarbamylase deficiency. *J. Pediatr.* Apr 2014;164(4):720-725 e726. PMID: 24485820
68. Berry SA, Lichter-Konecki U, Diaz GA, et al. Glycerol phenylbutyrate treatment in children with urea cycle disorders: pooled analysis of short and long-term ammonia control and outcomes. *Mol. Genet. Metab.* May 2014;112(1):17-24. PMID: 24630270
69. Batshaw ML, Groft SC, Krischer JP. Research into rare diseases of childhood. *JAMA.* May 7 2014;311(17):1729-1730. PMID: 24794360
70. Helman G, Pacheco-Colon I, Gropman AL. The urea cycle disorders. *Semin. Neurol.* Jul 2014;34(3):341-349. PMID: 25192511
71. Burrage LC, Jain M, Gandolfo L, Lee BH, Nagamani SC. Sodium phenylbutyrate decreases plasma branched-chain amino acids in patients with urea cycle disorders. *Mol. Genet. Metab.* Jul 3 2014. PMID: 25042691
72. Burrage LC, Nagamani SC, Campeau PM, Lee BH. Branched-chain amino acid metabolism: from rare Mendelian diseases to more common disorders. *Hum. Mol. Genet.* Sep 15 2014;23(R1):R1-8. PMID: 24651065, PMCID: PMC4170715
73. Batshaw ML, Tuchman M, Summar M, Seminara J. A longitudinal study of urea cycle disorders. *Mol. Genet. Metab.* Sep-Oct 2014;113(1-2):127-130. PMID: 25135652, PMCID: PMC4178008
74. Burrage LC, Jain M, Gandolfo L, Lee BH, Nagamani SC. Sodium phenylbutyrate decreases plasma branched-chain amino acids in patients with urea cycle disorders. *Mol. Genet. Metab.* Sep-Oct 2014;113(1-2):131-135. PMID: 25042691, PMCID: PMC4177960
75. Pacheco-Colon I, Fricke S, VanMeter J, Gropman AL. Advances in urea cycle neuroimaging: Proceedings from the 4th International Symposium on urea cycle disorders, Barcelona, Spain, September 2013. *Mol. Genet. Metab.* Sep-Oct 2014;113(1-2):118-126. PMID: 25066103, PMCID: PMC4177962

76. Sprouse C, King J, Helman G, et al. Investigating neurological deficits in carriers and affected patients with ornithine transcarbamylase deficiency. *Mol. Genet. Metab.* Sep-Oct 2014;113(1-2):136-141. PMID: 24881970, PMCID: PMC4458385
77. Burrage LC, Sun Q, Elsea SH, et al. Human recombinant arginase enzyme reduces plasma arginine in mouse models of arginase deficiency. *Hum Mol Genet.* 2015;24(22):6417-6427. PMID: 26358771, PMCID: PMC5007608
78. Kolker S, Dobbelaere D, Haberle J, et al. Networking Across Borders for Individuals with Organic Acidurias and Urea Cycle Disorders: The E-IMD Consortium. *JIMD reports.* 2015;22:29-38. PMID: 25701269, PMCID: PMC4486274
79. Pacheco-Colon I, Washington SD, Sprouse C, Helman G, Gropman AL, VanMeter JW. Reduced Functional Connectivity of Default Mode and Set-Maintenance Networks in Ornithine Transcarbamylase Deficiency. *PLoS ONE.* 2015;10(6):e0129595. PMID: 26067829, PMCID: PMC4466251
80. Shi D, Allewell NM, Tuchman M. From Genome to Structure and Back Again: A Family Portrait of the Transcarbamylases. *Int. J. Mol. Sci.* 2015;16(8):18836-18864. PMID: 26274952, PMCID: PMC4581275
81. Waisbren SE, He J, McCarter R. Assessing Psychological Functioning in Metabolic Disorders: Validation of the Adaptive Behavior Assessment System, Second Edition (ABAS-II), and the Behavior Rating Inventory of Executive Function (BRIEF) for Identification of Individuals at Risk. *JIMD reports.* Feb 25 2015. PMID: 25712381
82. Chong JX, Burrage LC, Beck AE, et al. Autosomal-Dominant Multiple Pterygium Syndrome Is Caused by Mutations in MYH3. *Am. J. Hum. Genet.* May 7 2015;96(5):841-849. PMID: 25957469
83. Caldovic L, Abdikarim I, Narain S, Tuchman M, Morizono H. Genotype-Phenotype Correlations in Ornithine Transcarbamylase Deficiency: A Mutation Update. *Journal of genetics and genomics = Yi chuan xue bao.* May 20 2015;42(5):181-194. PMID: 26059767, PMCID: PMC4565140
84. Boyer SW, Barclay LJ, Burrage LC. Inherited Metabolic Disorders: Aspects of Chronic Nutrition Management. *Nutr. Clin. Pract.* Jun 16 2015. PMID: 26079521, PMCID: PMC4515158
85. Lee B, Diaz GA, Rhead W, et al. Blood ammonia and glutamine as predictors of hyperammonemic crises in patients with urea cycle disorder. *Genet. Med.* Jul 2015;17(7):561-568. PMID: 25503497, PMCID: PMC4465427
86. Krivitzky LS, Walsh KS, Fisher EL, Berl MM. Executive functioning profiles from the BRIEF across pediatric medical disorders: Age and diagnosis factors. *Child neuropsychology : a journal on normal and abnormal development in childhood and adolescence.* Jul 6 2015:1-19. PMID: 26143938
87. Boyer SW, Barclay LJ, Burrage LC. Inherited Metabolic Disorders: Aspects of Chronic Nutrition Management. *Nutr. Clin. Pract.* Aug 2015;30(4):502-510. PMID: 26079521, PMCID: PMC4515158

- 88.** Pferdehirt R, Jain M, Blazo MA, Lee B, Burrage LC. Catel-Manzke Syndrome: Further Delineation of the Phenotype Associated with Pathogenic Variants in. *Molecular genetics and metabolism reports*. Sep 1 2015;4:89-91. PMID: 26366375, PMCID: PMC4563870
- 89.** Kolker S, Cazorla AG, Valayannopoulos V, et al. The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 1: the initial presentation. *J. Inherit. Metab. Dis.* Nov 2015;38(6):1041-1057. PMID: 25875215
- 90.** Kolker S, Valayannopoulos V, Burlina AB, et al. The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 2: the evolving clinical phenotype. *J. Inherit. Metab. Dis.* Nov 2015;38(6):1059-1074. PMID: 25875216
- 91.** Burrage LC, Charng WL, Eldomery MK, et al. De Novo GMNN Mutations Cause Autosomal-Dominant Primordial Dwarfism Associated with Meier-Gorlin Syndrome. *Am. J. Hum. Genet.* Dec 3 2015;97(6):904-913. PMID: 26637980, PMCID: PMC4678788
- 92.** Heringer J, Valayannopoulos V, Lund AM, et al. Impact of age at onset and newborn screening on outcome in organic acidurias. *J. Inherit. Metab. Dis.* Dec 21 2015. PMID: 26689403
- 93.** Burrage LC, Miller MJ, Wong LJ, et al. Elevations of C14:1 and C14:2 Plasma Acylcarnitines in Fasted Children: A Diagnostic Dilemma. *J. Pediatr.* 2016;169:208-213.e202. PMID: 26602010, PMCID: PMC4729603
- 94.** Shapiro E, Bernstein J, Adams HR, et al. Neurocognitive clinical outcome assessments for inborn errors of metabolism and other rare conditions. *Mol. Genet. Metab.* Jun 2016;118(2):65-69. PMID: 27132782